Subscribe To

Price Alert Latest News Economic Calendar News

TCON / TRACON Pharmaceuticals and China-based Eucure Biopharma strike partnership to develop clinical-stage CTLA-4 antibody YH001

TRACON Pharmaceuticals Inc. has entered into a collaborative partnership agreement with China-based Eucure Biopharma for the development of CTLA-4 antibody YH001 in multiple oncology indications, including soft tissue sarcoma. Under the terms of the agreement, TRACON said it will be responsible for the clinical development and commercialization of YH001 in North America, with the majority of the development activities expected to occur in the US. Read More

Demo Live Account See Partner Details

Content Topics

Tracon

Pharmaceuticals

China

Based

Eucure

Biopharma

Strike

China based

Partnership

Develop

Clinical stage

Ctla 4

Antibody

Stock

TCON

Posted: Oct 11 2021, 08:55

Author Name: Proactive Investors

TCON News

By GlobeNewsWire
September 5, 2023

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost

By Seeking Alpha
August 14, 2023

TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2023 Earnings Call August 14, 2023 4:30 PM ET Company Participants Charles P. Theuer - President and CE

By GlobeNewsWire
August 2, 2023

TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-

By Seeking Alpha
May 10, 2023

TRACON Pharmaceuticals, Inc. (TCON) Q1 2023 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, Presid

By InvestorPlace
April 25, 2023

Why Is TRACON Pharma (TCON) Stock Down 51% Today?

TRACON Pharmaceuticals (NASDAQ: TCON ) stock is falling on Tuesday following an update on a legal battle with I-Mab (NASDAQ: IMAB ). The bad news fo

By Zacks Investment Research
March 14, 2023

Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade

Tracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

By Seeking Alpha
March 8, 2023

TRACON Pharmaceuticals, Inc. (TCON) Q4 2022 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, Presi

By Seeking Alpha
November 30, 2022

Revisiting Tracon Pharmaceuticals

Today, we look back in on clinical stage developmental firm TRACON Pharmaceuticals for the first time since early 2021. The company's primary drug can

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.